Benchmark analyst Mike Hickey reiterates Marcus (NYSE:MCS) with a Buy and maintains $20 price target.
Applied Molecular Transport Completes Enrollment Of Phase 2 LOMBARD Monotherapy Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis
Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with
